<DOC>
	<DOCNO>NCT02254174</DOCNO>
	<brief_summary>Assessment relative bioavailability fix dose combination tiotropium salmeterol compare free dose combination market product tiotropium salmeterol ( Spiriva® Serevent® Diskus® ) . Assessment relative bioavailability fix dose combination tiotropium salmeterol compare tiotropium salmeterol administer individual mono substance market product . Assessment safety tolerability fix combination tiotropium salmeterol PE ( Polyethylene ) capsule administer via HandiHaler® 2</brief_summary>
	<brief_title>Relative Bioavailability Tiotropium Salmeterol After Inhalation Fixed Combined Dose Compared Monocomponents Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Healthy male base upon complete medical history , include physical examination , regard vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead ECG ( electrocardiogram ) measurement , clinical laboratory test . There find deviate normal clinical relevance . There evidence clinically relevant concomitant disease 2 . Age ≥21 ≤50 year 3 . BMI ≥18.5 &lt; 30 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation 1 . Any finding medical examination ( include BP , PR , ECG measurement ) deviate normal clinical relevance 2 . Evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) judge clinically relevant investigator 8 . Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives respective drug prior randomisation 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior enrolment study study 10 . Participation another trial investigational drug within 2 month prior randomisation 11 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 12 . Inability refrain smoke trial day judge investigator 13 . Alcohol abuse ( 40 g alcohol day ) 14 . Drug abuse 15 . Blood donation ( 100 mL blood within 4 week prior randomisation trial ) 16 . Excessive physical activity within 1 week prior randomisation trial 17 . Any laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen study centre The following exclusion criterion specific study due know class side effect profile ß2mimetics : 19 . Asthma history pulmonary hyperreactivity 20 . Hyperthyrosis 21 . Allergic rhinitis need treatment 22 . Clinically relevant cardiac arrhythmia 23 . Paroxysmal tachycardia ( &gt; 100 beat per minute ) The following exclusion criterion specific study due know class side effect profile tiotropium : 24 . Hypersensitivity tiotropium and/or relate drug class</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>